Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study-Reference-Cited by-同舟云学术

Evaluation of the prognostic value of all four HER family receptors in patients with metastatic breast cancer treated with trastuzumab: A Hellenic Cooperative Oncology Group (HeCOG) study

Published:2018-12-06 Issue:12 Volume:13 Page:e0207707
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Koutras Angelos^ORCID,Lazaridis Georgios,Koliou Georgia-Angeliki,Kouvatseas George,Christodoulou Christos,Pectasides Dimitrios,Kotoula Vassiliki,Batistatou Anna,Bobos Mattheos,Tsolaki Eleftheria,Papadopoulou Kyriaki,Pentheroudakis George,Papakostas Pavlos,Pervana Stavroula,Petraki Kalliopi,Chrisafi Sofia^ORCID,Razis Evangelia,Psyrri Amanda,Bafaloukos Dimitrios,Kalogeras Konstantine T.,Kalofonos Haralambos P.,Fountzilas George

Funder

Roche Hellas SA

Hellenic Cooperative Oncology Group

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference51 articles.

1. Fifteen-year trends in metastatic breast cancer survival in Greece;U Dafni;Breast Cancer Res Treat,2010

2. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene;DJ Slamon;Science,1987

3. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2;DJ Slamon;N Engl J Med,2001

4. Oncogenic growth factor receptors: implications for signal transduction therapy;Y Mosesson;Semin Cancer Biol,2004

5. Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications;BN Rexer;Crit Rev Oncog,2012

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Significance of Major Angiogenesis-Related Effectors in Patients with Metastatic Breast Cancer Treated with Trastuzumab-based Regimens;Cancer Research and Treatment;2021-11-17

2. Evaluation of the Role of p95 HER2 Isoform in Trastuzumab Efficacy in Metastatic Breast Cancer;Anticancer Research;2021-04

3. Targeting HER2 in breast cancer: new drugs and paradigms on the horizon;Exploration of Targeted Anti-tumor Therapy;2021-03-23

4. Focus on Cdc42 in Breast Cancer: New Insights, Target Therapy Development and Non-Coding RNAs;Cells;2019-02-11